Journal of Medicinal Chemistry · 2002 · 60 citations · 7 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryOrganic ChemistryStructure-activity RelationshipsAnalgesiaAnalgesic PharmacologyStructure-activity Relationship AnalysisMuscle Relaxant EffectsMuscle Relaxant TherapyPharmacological Pain ReliefPhase I Clinical Trials
The design of rigid cyclic analogues derived from cinnamamide 1, (E)-N-cyclopropyl-3-(3-fluorophenyl)prop-2-enamide, and beta-methylcinnamamide 2, (E)-N-cyclopropyl-3-(3-fluorophenyl)but-2-enamide, has led to the discovery of the potent, centrally acting muscle relaxant (E)-2-(4,6-difluoro-1-indanylidene)acetamide, 17. Compound 17 also possesses potent antiinflammatory and analgesic activity. This paper describes the synthesis and the muscle relaxant, antiinflammatory, and analgesic structure-activity relationships of 17 and 67 of its analogues. Compound 17 has been taken into phase I clinical trials.
7